Novartis | NVS - Operating Profit

Stock Price
149.86
Daily Change
-1.21 -0.80%
Monthly
8.70%
Yearly
41.99%
Q1 Forecast
145.07

Novartis reported $4.58B in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Bausch Health Companies USD 717M 260M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 2.79B 764M Sep/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Prestige Brands USD 79.67M 7.91M Sep/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Supernus Pharmaceuticals USD -60.18M 72.32M Sep/2025
Zoetis USD 936M 63M Sep/2025